Skip to main content
Caplight Logo









Neomorph

Neomorph

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://neomorph.com/

Last Round

Series B

Apr 13, 2026

Total Funding Raised

$209M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Neomorph is a biotechnology company that develops molecular glue degraders to target and destroy disease-causing proteins that have historically been considered undruggable.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

molecular gluetargeted protein degradationTPDdrug discovery platformundruggable proteinssmall-molecule therapeuticsbiobuckscomputational drug discoveryAI drug discoveryprotein degraderbiotech platformoncology therapeuticsimmunologybiopharma partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neomorph Comparables

Compare Neomorph with similar companies based on industry and business-model similarity.

Neomorph comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TRIANA Biomedicines
87%
Magnet Biomedicine
86%
Plexium
86%

Neomorph Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 13, 2026
Series ADec 22, 2020
SeedMar 31, 2020

Key People

Founding team and executive leadership

Phil Chamberlain

Co-Founder, President and CEO

Founding Team

Neomorph Investors

Notable investors and investment history

Neomorph investors
InvestorRounds
Deerfield ManagementSeries B, Series A
Binney Street CapitalSeries B
Alexandria Venture InvestmentsSeries B
Longwood FundSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Grew 15% QoQ, from 84 to 97 employees.

  • Apr 14, 2026

    Partnering with the Center for Protein Degradation at Dana-Farber Cancer Institute.

Neomorph Filings

Explore SEC and related filing metadata, where available.

Neomorph filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neomorph's valuation, stock price, and market status.

Is Neomorph a public or private company?

Neomorph is a private company.

What is the current stock price of Neomorph?

Neomorph is a private company with no public stock price. No recent secondary market data is available.

How much is Neomorph worth (valuation)?

Valuation information for Neomorph is not publicly available.

Can I buy Neomorph stock?

Neomorph shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neomorph's last funding round?

Neomorph's most recent funding round was Series B on April 13, 2026.

Who are the main investors in Neomorph?

Key investors in Neomorph include Deerfield Management.

Will Neomorph IPO soon?

No public IPO plans have been announced for Neomorph.

How can I track Neomorph secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neomorph's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range78
Year Founded2020
Last FundingApr 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?